Earnings call transcript: XVivo Q2 2025 reveals sales dip, stock plunges

XVivo Perfusion AB reported a challenging Q2 2025, with net sales declining 11% organically to SEK 178 million, driven by a slower lung market, customer destocking, and negative currency effects, leading to a significant 27.74% pre-market stock price drop. Despite maintaining a stable 74% gross margin and strong liquidity, the company acknowledged the disappointing quarter. However, management highlighted robust growth in specific segments, including US Lung sales (+26%) and European Liver sales (+32%), and remains committed to strategic initiatives such as the imminent European launch of its heart product and a planned US liver clinical trial, underscoring long-term optimism in the organ transplantation market.

Analysis

XVivo Perfusion AB reported a significantly challenging second quarter for 2025, triggering a 27.74% pre-market decline in its stock price. The primary driver was a top-line miss, with net sales of SEK 178 million reflecting an 11% organic decline, further impacted by a 6% negative currency effect. Management attributed this underperformance to a confluence of factors, most notably a slowdown in the US lung transplant market and significant destocking by its single largest customer, which saw its own sales from XVivo reduced by approximately 40%. Heart sales also collapsed to SEK 3 million from SEK 19 million year-over-year, creating a difficult comparison due to prior-year trial revenues. Despite these headwinds, the company's financial fundamentals show resilience; the gross margin remained stable at a strong 74%, and the adjusted EBITDA margin was 13%, demonstrating a scalable business model where profitability is highly sensitive to sales volume. Moreover, pockets of strong execution were evident, with US lung sales outside the key destocking account growing 26%, European liver sales increasing 32%, and US kidney disposable sales rising 47%. The long-term thesis, as articulated by the CEO, remains centered on major catalysts, including the imminent European launch of its heart product, which showed a 76% risk reduction in severe PDD in trials, and the planned Q3 2025 start of a US liver clinical trial.

Key Decisions for Investors

• Investors should closely monitor the activity of XVivo's largest US lung customer and broader EVLP market trends, as a stabilization in destocking and a return to growth in this core segment are critical for near-term revenue recovery.
• The stock's sharp decline to a 52-week low may present a valuation opportunity for those confident in the long-term pipeline, but this must be weighed against the high volatility, indicated by a beta of 1.91, and significant execution risk.
• Pay close attention to near-term catalysts, specifically the final regulatory approval and subsequent commercial ramp-up for the heart product in Europe and the initiation of the US liver trial in Q3, as these are key inflection points for the investment case.
• Consider the bifurcation in performance: weigh the severe short-term headwinds in the core lung segment against the demonstrated underlying growth in new customer acquisition, liver, and kidney segments to assess if current issues are temporary or structural.